Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study

#2094

Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.

Aim(s): To evaluate lanreotide autogel (LAN) plus TMZ in patients (pts) with progressive advanced/metastatic G1/G2 GEP-NET (or unknown primary).

Materials and methods: SONNET is an open, prospective, phase 2 study. The primary endpoint was the rate of disease control (DCR), defined as SD + PR + CR at 6 mo of a combination therapy of LAN and TEM. Non-functioning NET pts without progression at 6 mo were randomized to 6-mo LAN maintenance or watch and wait. Functioning NET pts with benefit continued on LAN.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pavel M, Denecke T, Lahner H, Hörsch D, Rinke A,

Keywords: lanreotide, temozolomide, somatostatin analogues, combination therapy, progressive advanced NET, SONNET,